Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409154269> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2409154269 endingPage "65" @default.
- W2409154269 startingPage "358" @default.
- W2409154269 abstract "Clinical benefit in oncology patients can only be derived from coordinated and successive experimental trials. The following consensus thus emerged from the working party: The assessment of tolerance during clinical trials requires the actuarial rate of acute adverse events (AE) to be registered and the development of epidemiological structures involved in long-term assessment of AE. Experimental trials have to be assessed according to descriptive epidemiological data (generated in France and Europe) and completed with observational studies on post-marketing medical practice. The principle of an a priori authorization given by the Afssaps for gene and cell therapy trials was legalised in October 2001. The working group spoke strongly in favour of authorizing early trials only validating the process, and for reasonable objectives in terms of viral security assessment of annex therapeutic products. With regard to the development of new antiproliferative agents, the active dose (or optimal biological dose) replaces the maximal tolerable dose. Early efficacy criteria could be biological and specific. With cumulative subacute rather than acute toxicity, these agents can not be properly evaluated with a short term benefit/risk ratio as is done for cytotoxic drugs. Elderly people constitute a fragile, heterogeneous and increasing population, in whom adequate assessment of anticancer agents is mandatory. It is important to promote controlled clinical trials in children and to systematically monitor them over a very long period of time. Only rare tumours may be considered as orphan situations. Finally, a list of all clinical trials conducted in oncology should be made by the Afssaps, with the help of the FNLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) who have already begun this work." @default.
- W2409154269 created "2016-06-24" @default.
- W2409154269 creator A5004559129 @default.
- W2409154269 creator A5024604492 @default.
- W2409154269 creator A5052540373 @default.
- W2409154269 creator A5053928970 @default.
- W2409154269 date "2002-11-09" @default.
- W2409154269 modified "2023-10-03" @default.
- W2409154269 title "[Clinical trials in oncology: specific methodology problems]." @default.
- W2409154269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12422556" @default.
- W2409154269 hasPublicationYear "2002" @default.
- W2409154269 type Work @default.
- W2409154269 sameAs 2409154269 @default.
- W2409154269 citedByCount "0" @default.
- W2409154269 crossrefType "journal-article" @default.
- W2409154269 hasAuthorship W2409154269A5004559129 @default.
- W2409154269 hasAuthorship W2409154269A5024604492 @default.
- W2409154269 hasAuthorship W2409154269A5052540373 @default.
- W2409154269 hasAuthorship W2409154269A5053928970 @default.
- W2409154269 hasConcept C107130276 @default.
- W2409154269 hasConcept C108759981 @default.
- W2409154269 hasConcept C126322002 @default.
- W2409154269 hasConcept C143998085 @default.
- W2409154269 hasConcept C177713679 @default.
- W2409154269 hasConcept C197934379 @default.
- W2409154269 hasConcept C23131810 @default.
- W2409154269 hasConcept C2777589142 @default.
- W2409154269 hasConcept C2908647359 @default.
- W2409154269 hasConcept C38652104 @default.
- W2409154269 hasConcept C41008148 @default.
- W2409154269 hasConcept C535046627 @default.
- W2409154269 hasConcept C60644358 @default.
- W2409154269 hasConcept C71924100 @default.
- W2409154269 hasConcept C86803240 @default.
- W2409154269 hasConcept C99454951 @default.
- W2409154269 hasConceptScore W2409154269C107130276 @default.
- W2409154269 hasConceptScore W2409154269C108759981 @default.
- W2409154269 hasConceptScore W2409154269C126322002 @default.
- W2409154269 hasConceptScore W2409154269C143998085 @default.
- W2409154269 hasConceptScore W2409154269C177713679 @default.
- W2409154269 hasConceptScore W2409154269C197934379 @default.
- W2409154269 hasConceptScore W2409154269C23131810 @default.
- W2409154269 hasConceptScore W2409154269C2777589142 @default.
- W2409154269 hasConceptScore W2409154269C2908647359 @default.
- W2409154269 hasConceptScore W2409154269C38652104 @default.
- W2409154269 hasConceptScore W2409154269C41008148 @default.
- W2409154269 hasConceptScore W2409154269C535046627 @default.
- W2409154269 hasConceptScore W2409154269C60644358 @default.
- W2409154269 hasConceptScore W2409154269C71924100 @default.
- W2409154269 hasConceptScore W2409154269C86803240 @default.
- W2409154269 hasConceptScore W2409154269C99454951 @default.
- W2409154269 hasIssue "4" @default.
- W2409154269 hasLocation W24091542691 @default.
- W2409154269 hasOpenAccess W2409154269 @default.
- W2409154269 hasPrimaryLocation W24091542691 @default.
- W2409154269 hasRelatedWork W1971968142 @default.
- W2409154269 hasRelatedWork W2013270427 @default.
- W2409154269 hasRelatedWork W2047498965 @default.
- W2409154269 hasRelatedWork W2156007980 @default.
- W2409154269 hasRelatedWork W224950321 @default.
- W2409154269 hasRelatedWork W2308998463 @default.
- W2409154269 hasRelatedWork W2312851930 @default.
- W2409154269 hasRelatedWork W2409154269 @default.
- W2409154269 hasRelatedWork W2412178974 @default.
- W2409154269 hasRelatedWork W2969890384 @default.
- W2409154269 hasVolume "57" @default.
- W2409154269 isParatext "false" @default.
- W2409154269 isRetracted "false" @default.
- W2409154269 magId "2409154269" @default.
- W2409154269 workType "article" @default.